Amniotic fluid embolism (AFE) is a rare, life-threatening emergency that occurs when components of amniotic fluid enter a mother’s bloodstream and trigger a severe immune reaction during or shortly after labor. It affects roughly 1 in 15,200 deliveries in North America. Despite its name, AFE is not a simple blockage of blood vessels. It behaves more like a massive allergic reaction, which is why researchers have proposed renaming it “anaphylactoid syndrome of pregnancy.”
Why the Name Is Misleading
For decades, doctors believed that fetal cells and debris physically clogged the blood vessels in the mother’s lungs, much like a blood clot causes a pulmonary embolism. That theory has largely been abandoned. Studies have shown that even if the entire volume of amniotic fluid entered a mother’s circulation, the fetal cells it contains would block only about one in a million tiny lung capillaries, an obstruction so small it would be clinically undetectable.
What actually happens is an immune-mediated cascade. When fetal antigens enter the mother’s bloodstream, they appear to trigger a response similar to what happens during severe systemic inflammation. The complement system, a part of the immune system that normally fights infection, becomes intensely activated. In women with AFE, complement protein levels drop to less than half the levels seen in normal postpartum women, a sign that the system has been massively consumed in the reaction. This inflammatory storm suppresses heart function and activates widespread, uncontrolled blood clotting throughout the body.
The Classic Triad of Symptoms
AFE typically strikes during labor or in the minutes immediately following delivery. The presentation is dramatic and fast. In many cases, a brief period of anxiety, agitation, or an overwhelming sense of doom comes first. Then three hallmark problems develop in rapid succession:
- Sudden oxygen deprivation (hypoxia): The mother may gasp for air, turn blue, or lose consciousness as her lungs fail to exchange oxygen properly.
- Dangerously low blood pressure (hypotension): The heart’s pumping ability is suppressed by the inflammatory response, causing cardiovascular collapse.
- Uncontrolled bleeding (coagulopathy): Up to 83% of AFE cases involve disseminated intravascular coagulation, or DIC, a condition where the blood’s clotting factors are used up so rapidly that the body can no longer stop bleeding anywhere.
These three problems don’t always appear simultaneously. The bleeding disorder sometimes shows up only after initial resuscitation efforts stabilize the heart and lungs. In rare cases, abnormal bleeding is the only sign, with no obvious cardiorespiratory collapse at all.
Who Is at Higher Risk
Because AFE is so rare, pinpointing risk factors has been difficult. Recent research has identified placental abnormalities, particularly a group of conditions called placenta accreta spectrum (PAS), as an important risk factor. When PAS is combined with placental abruption and preterm birth, the estimated risk of AFE rises to 6.5%, a striking increase compared to the baseline rate. Women over 40 with these placental complications carry a risk around 0.4%. For low-risk term vaginal deliveries, the risk drops to approximately 0.001%.
Other factors that have been associated with AFE in population studies include labor induction, cesarean delivery, and older maternal age, though none of these are strong enough predictors to screen for or prevent the condition.
How AFE Is Diagnosed
There is no blood test or imaging study that confirms AFE. The Society for Maternal-Fetal Medicine explicitly recommends against relying on any specific lab test to confirm or rule it out. It remains a clinical diagnosis, meaning doctors identify it based on the pattern of symptoms: sudden cardiovascular collapse, breathing failure, and bleeding problems occurring during or just after delivery, with no other explanation.
That last part matters. The medical team must first rule out other conditions that can look similar, including pulmonary embolism from a blood clot, heart attack, severe allergic reactions to medications, placental abruption, uterine rupture, and eclampsia. AFE is essentially a diagnosis of exclusion, reached after these other emergencies have been considered.
One early clue that has shown promise is a rapidly dropping fibrinogen level. Fibrinogen is a protein the body uses to form blood clots, and in AFE it plummets faster than hemoglobin does. A high ratio of hemoglobin to fibrinogen may help medical teams recognize AFE-related bleeding earlier, potentially buying time for intervention.
What Happens During Treatment
Treatment for AFE is supportive, meaning there is no cure or antidote. The immediate priority is keeping the mother alive through aggressive resuscitation: restoring oxygen, supporting blood pressure, and replacing blood products to combat DIC. If the baby has not yet been delivered, an emergency cesarean is typically performed within minutes, both to save the baby and to improve the mother’s chances by reducing the body’s demands.
A newer approach called the A-OK protocol has gained attention as an early intervention. It combines three medications given intravenously: one that blocks a nerve reflex contributing to cardiovascular collapse, one that blocks serotonin (a chemical messenger involved in the inflammatory cascade), and one anti-inflammatory drug that may help slow the runaway clotting process. This protocol is still considered adjunctive, meaning it supplements rather than replaces standard resuscitation, but early case reports have been encouraging enough that many obstetric teams now keep the medications readily available.
Survival and Outcomes
AFE was once considered almost universally fatal. Modern data tells a more hopeful story. A U.S. study found an overall maternal mortality rate of 12.9%, a significant improvement over historical estimates that placed mortality above 60%. The improvement likely reflects better recognition, faster response times, and advances in critical care rather than any single treatment breakthrough.
Survival, however, does not always mean full recovery. Because the brain is deprived of oxygen during the collapse, neurological injury is a concern for mothers who survive the initial event. Babies born during an AFE episode also face risks from oxygen deprivation, and outcomes depend heavily on how quickly delivery occurs after symptoms begin.
The rarity of AFE means that even experienced obstetricians may encounter it only once or twice in a career. Hospitals with rapid-response obstetric teams and readily available blood products tend to have better outcomes, simply because every minute counts once the cascade begins.